Brief: Santhera Pharmaceuticals H1 Operating Income CHF -6.562 Million
30/09/2026 06:01
BRIEF-Santhera Pharmaceuticals H1 Operating Income CHF -6.562 Million Sep 30 (Reuters) - Santhera Pharmaceuticals H1 operating expenses CHF -25.007 million.
- H1 net income CHF -21.526 million
- H1 EPS CHF -1.5
Recent news on Santhera Pharmaceuticals Holding AG
See all newsSwitzerland's Santhera Pharma H1 revenue soars on AGAMREE sales, milestones
Brief: Santhera Pharmaceuticals H1 Operating Income CHF -6.562 Million
Brief: Santhera Says NXERA Plans To Submit South Korea Marketing Authorization Application 2026
Brief: Santhera Gets Positive CHMP Opinion To Expand Agamree (Vamorolone) Use
Brief: Santhera Pharmaceuticals H1 Operating Income CHF -35.444 Million